San Diego, Ca., USA - February 4, 2010, San Diego, Ca., USA - Adventrx Pharmaceuticals announced that, Brian M. Culley, chief business officer and a senior vice president, will serve as CEO and Patrick L. Keran, general counsel, will serve as president and chief operating officer, both promotions effective immediately.
Article continues below
Mr. Culley has served as the Company’s Chief Executive Officer since February 2010. Prior to this, beginning in February 2009, he served as the Company’s Principal Executive Officer and, beginning in January 2007, Chief Business Officer and a Senior Vice President. Mr. Culley served as Vice President, Business Development upon joining the Company in December 2004, and was appointed Senior Vice President, Business Development in February 2006.
From 2002 until 2004, Mr. Culley managed all strategic collaborations and licensing agreements for iTherx, Inc. (formerly, Immusol, Inc.) in San Diego, where his most recent title was director of business development and marketing. From 1999 until 2000, he was a licensing and marketing associate at the University of California, San Diego, department of technology transfer & intellectual property services and from 1996 to 1999, he was a research associate for Neurocrine Biosciences, Inc., where he performed drug discovery research.
Mr. Culley has over 17 years of experience in the biotechnology industry, including deal structure and negotiation, licensing, due diligence, market and competitive research, and venture funding. He received a B.S. in biology from Boston College, an M.S. in biochemistry from the University of California, Santa Barbara and an M.B.A. from The Johnson School of Business at Cornell University with an emphasis on private equity and entrepreneurship.
Mr. Keran has served as the Company’s President & Chief Operating Officer since February 2010. Mr. Keran also serves as the Company’s Secretary, a position he has held since September 2006. Prior to this, beginning in August 2006, he served as the Company’s General Counsel and, beginning in January 2007, Vice President, Legal.
From April 2004 to August 2006, Mr. Keran was associate general counsel at Isis Pharmaceuticals, a publicly held drug discovery and development company. From February 2003 to April 2004, Mr. Keran practiced corporate law at the law firm of Heller Ehrman LLP, specializing in public and private financings, licensing arrangements, mergers and acquisitions and corporate governance matters. ■